Development of hot-melt extrusion as a novel technique for the ...
Development of hot-melt extrusion as a novel technique for the ...
Development of hot-melt extrusion as a novel technique for the ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CHAPTER 4: TASTE MASKING OF PARACETAMOL BY HOT MELTEXTRUSION: AN IN VITRO AND IN VIVO EVALUATION1.0 IntroductionThe t<strong>as</strong>te m<strong>as</strong>king <strong>of</strong> bitter APIs is a major challenge especially <strong>for</strong> <strong>the</strong> development<strong>of</strong> orally disintegrating tablets (ODT) in pharmaceutical industry. Several approaches havebeen reported which involve fluidized-bed coating, supercritical fluids and coacervationapproaches where effective t<strong>as</strong>te-m<strong>as</strong>king is achieved by applying polymeric coating layer tocreate a physical barrier around <strong>the</strong> drug [1, 2] . O<strong>the</strong>r alternatives involve <strong>the</strong> use <strong>of</strong>complexing agents (cylcodextrins, ion exchange resins) through <strong>the</strong> <strong>for</strong>mation <strong>of</strong> inclusioncomplexes or resonates [3] . Recently, t<strong>as</strong>te m<strong>as</strong>king approaches have employed t<strong>as</strong>tesuppressants molecules by blocking <strong>the</strong> gap junction channels ad hemichannels and thussuppressing <strong>the</strong> drugs t<strong>as</strong>te [4,5] . However, <strong>the</strong>re is an enormous need <strong>for</strong> more robust, costeffective and e<strong>as</strong>y to scale – up t<strong>as</strong>te m<strong>as</strong>king technologies. HME is a continuous, one stepprocess that h<strong>as</strong> been used <strong>for</strong> <strong>the</strong> development <strong>of</strong> solid dispersions <strong>of</strong> active substances <strong>for</strong>various applications [6, 7] .Hot-<strong>melt</strong> <strong>extrusion</strong> (HME) h<strong>as</strong> been employed <strong>as</strong> a <strong>novel</strong> <strong>technique</strong> <strong>for</strong> <strong>the</strong><strong>for</strong>mulation <strong>of</strong> oral solid dosage <strong>for</strong>ms in pharmaceutical industries in <strong>the</strong> l<strong>as</strong>t decade. It w<strong>as</strong>initially used in food and pl<strong>as</strong>tic industry but h<strong>as</strong> attracted significant interest in <strong>the</strong>pharmaceutical manufacturing <strong>for</strong> <strong>the</strong> development <strong>of</strong> robust <strong>for</strong>mulations. HME can be usedto develop various <strong>for</strong>mulations such <strong>as</strong> sustained rele<strong>as</strong>e matrices [8–11] . It h<strong>as</strong> also beenintroduced <strong>for</strong> t<strong>as</strong>te m<strong>as</strong>king purposes <strong>of</strong> bitter APIs by involving <strong>the</strong> use <strong>of</strong> t<strong>as</strong>te m<strong>as</strong>kingpolymers that create solid dispersions to prevent bitter drugs from coming in contact with <strong>the</strong>patient‘s t<strong>as</strong>te buds [12–15] .T<strong>as</strong>te m<strong>as</strong>king can be achieved through intermolecular <strong>for</strong>ces (e.g. hydrogen bonding)between <strong>the</strong> active substance and <strong>the</strong> polymer matrix by processing oppositely chargedcompounds [1, 2] . In addition, solid dispersions in which <strong>the</strong> drug is molecularly dispersedwithin <strong>the</strong> polymer matrix have shown effectivenes <strong>for</strong> m<strong>as</strong>king <strong>of</strong> <strong>the</strong> drug‘s unple<strong>as</strong>antt<strong>as</strong>te. Successful t<strong>as</strong>te m<strong>as</strong>king requires development <strong>of</strong> HME processing conditions,drug/polymer ratio and selection <strong>of</strong> <strong>the</strong> appropriate <strong>for</strong>mulation components (Hansensolubility parameters). HME can be used <strong>for</strong> <strong>the</strong> development <strong>of</strong> robust <strong>for</strong>mulations withincre<strong>as</strong>ed patient palatability and compliance. T<strong>as</strong>te m<strong>as</strong>king evaluation <strong>of</strong> pharmaceuticaldosage <strong>for</strong>ms is usually carried out by human t<strong>as</strong>te panels (volunteers) and it can be used <strong>for</strong>fur<strong>the</strong>r product optimization. However, <strong>the</strong> t<strong>as</strong>te <strong>as</strong>sessment is subject to <strong>the</strong> individuals64 | P a g e